ABSTRACT
In recent years, translational medicine has become more and more widely used in the field of tumor. This article summarized the research progress in the field of translational medical tumors in the last few months, focusing on the summary analysis of breakthrough research results on tumor heterogeneity, drug resistance, pathogenesis and metastasis, in order to provide novel and cutting-edge research trends in the field of tumor for oncology researchers and clinicians, and promote the transformation of basic research results into clinical diagnosis and treatment.
ABSTRACT
Translational medicine is a new research system for rapid translation from basic research achievement to clinical treatment. This article summarized the research progress in the field of translational medicine in the recent months, and carried out an inventory of the frontier from important journals (such as Nature, Science, J Clin Invest, Nat Genet, Cell, Eur Heart J) in order to provide references for scientists and doctors, and promote the translation from basic medicine to clinical diagnosis and treatment.
ABSTRACT
This article summarizes the research progress in the field of translational medicine in the recent months,and carries out an inventory of the frontier from important journals (such as Nature,Science,Clin Invest,Diabetes) in order to provide references for scientists and doctors.
ABSTRACT
<p><b>OBJECTIVE</b>To summarize the clinical characteristics as well as diagnosis and treatment in 1 case of acute myeloid leukemia(AML) with coexpression of Ph and inv(16).</p><p><b>METHODS</b>A series of clinical tests, the cellular morphological, immunological, cytogenetic and molecular biological examinations of leukemia cells were performed.</p><p><b>RESULTS</b>The clinical characteristics of this patient were very common. The cellular morphology is similar to the AML with inv(16). The leukemia cells were stained positively for CD13, CD33, CD34, CD117 and HLA-DR. Karyotypic analysis showed a complex chromosome abnormality including inv(16) and Ph, and the FISH analysis showed that the percentage of rearrangement of CBFβ allele was over that of the BCR-ABL fusion signals. The obvious adverse events did not occur in this patient within 3 years.</p><p><b>CONCLUSION</b>Ph as secondary aberration of inv(16) rarely occures in primary AML cases, and so far there have not been the clear criteria of diagnosis and treatment. The cytogenetic and molecular biology could provide the basis for diagnosis. Moreover, autologous hematopoietic stem cell transplantation combined with imatinib probably is one of the effective treatment methods.</p>
Subject(s)
Humans , Chromosome Aberrations , Chromosome Disorders , Chromosome Inversion , Fusion Proteins, bcr-abl , HLA-DR Antigens , Leukemia, Myeloid, Acute , Philadelphia ChromosomeABSTRACT
To investigate the chemical constituents of A. barbadensis, aqueous extract of the plant was subjected to preparative medium pressure liquid chromatography (MPLC). The chemical structures were mainly determined by spectroscopic evidences (UV, IR, HR-MS, 1H NMR, 13C NMR, HSQC, 1H-1H COSY and HMBC) and chemical methods. A new O, O, O-triglucosylated naphthalene derivative, together with two known 6-phenyl-2-pyrone derivatives and four 5-methylchromones, were isolated and identified as 1-((3-((4- O-beta-D-glucopyranosyl)-beta-D-xylopyranosyloxymethyl)-1-hydroxy-8-alpha-L-rhamnopyranosyloxy)naphthalene-2-y])-ethanone (1), 10-O-beta-D-glucopyranosyl aloenin (2), aloenin B (3), aloesin (4), 8-C-glucosyl-(R)-aloesol (5), 8-C-glucosyl-7-O-methyl-(S)-aloesol (6), and isoaloeresin D (7). Compound 1 is a novel naphthalene derivative and named as aloveroside B, compounds 2-3 are isolated from this Aloe species for the first time.